Although improved outcomes have been observed with the use of dual HER2-targeted regimens compared with a single HER2 blockade in patients with HER2+ BC, including those with HR+ tumors, in the advanced setting, almost all patients ultimately experience disease progression, and additional treatment strategies are needed to overcome resistance [27]. This evidence concerns the gene ERBB2 and breast cancer.